Melphalan
- Generic Name
- Melphalan
- Brand Names
- Alkeran, Evomela, Phelinun, Pepaxti
- Drug Type
- Small Molecule
- Chemical Formula
- C13H18Cl2N2O2
- CAS Number
- 148-82-3
- Unique Ingredient Identifier
- Q41OR9510P
- Background
Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard. Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-conditioning before hematopoietic stem cell transplant. It is...
- Indication
Melphalan is indicated for use as a high-dose conditioning treatment prior to hematopoietic stem cell transplantation in patients with multiple myeloma. It is also indicated for the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary.
...
- Associated Conditions
- Multiple Myeloma (MM), Unresectable Liver Metastasis, Unresectable Ovarian Cancer (Epithelial)
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-07
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 51
- Registration Number
- NCT00027560
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
High-Dose Melphalan Followed by Peripheral Stem Cell Transplant in Treating Patients With Amyloidosis
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2010-10-01
- Lead Sponsor
- Temple University
- Registration Number
- NCT00002810
- Locations
- 🇺🇸
Fox Chase-Temple Cancer Center CCOP Research Base, Philadelphia, Pennsylvania, United States
Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-01-06
- Lead Sponsor
- Herbert Irving Comprehensive Cancer Center
- Target Recruit Count
- 52
- Registration Number
- NCT00008307
- Locations
- 🇺🇸
Herbert Irving Comprehensive Cancer Center at Columbia University, New York, New York, United States
Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2017-07-12
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 36
- Registration Number
- NCT00006244
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-09-17
- Lead Sponsor
- EBMT Solid Tumors Working Party
- Target Recruit Count
- 460
- Registration Number
- NCT00005589
- Locations
- 🇩🇪
Universitaetsklinikum Goettingen, Goettingen, Germany
🇧🇪Institut Jules Bordet, Brussels, Belgium
🇧🇪U.Z. Gasthuisberg, Leuven, Belgium
Umbilical Cord Blood Transplantation in Treating Patients With High-Risk Hematologic Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-03-15
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 44
- Registration Number
- NCT00003335
- Locations
- 🇺🇸
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2021-08-13
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 361
- Registration Number
- NCT00003816
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Combination Chemotherapy With or Without Thalidomide in Treating Patients With Multiple Myeloma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-09-17
- Lead Sponsor
- Commissie Voor Klinisch Toegepast Onderzoek
- Target Recruit Count
- 450
- Registration Number
- NCT00028886
- Locations
- 🇧🇪
U.Z. Gasthuisberg, Leuven, Belgium
🇳🇱Isala Klinieken - locatie Sophia, Zwolle, Netherlands
🇳🇱Academisch Medisch Centrum at University of Amsterdam, Amsterdam, Netherlands
Combination Chemotherapy Followed by Surgery and Peripheral Stem Cell or Bone Marrow Transplantation in Treating Infants With Newly Diagnosed Neuroblastoma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-09-17
- Lead Sponsor
- European Infant Neuroblastoma Study Group - 1999
- Registration Number
- NCT00025649
- Locations
- 🇸🇪
Ostra Sjukhuset, Gothenburg, Sweden
🇫🇷Centre Hospitalier Regional de Purpan, Toulouse, France
🇳🇴Rikshospitalet University Hospital, Oslo, Norway
High-Dose Chemotherapy Compared With Standard Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer That Has Been Removed During Surgery
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-09-17
- Lead Sponsor
- EBMT Solid Tumors Working Party
- Registration Number
- NCT00004921
- Locations
- 🇩🇪
Klinikum Nuernberg - Klinikum Nord, Nuernberg, Germany
🇮🇹Ospedale San Bortolo, Vicenza, Italy
🇦🇹Sozialmedizinisches Zentrum Ost - Donauspital, Vienna, Austria
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.